At the news
? NEUTRALIMPACT 3/10 SC 13D/A filed Nov 2, 2026 at 16:20 ET
Frazier Life Sciences filed Amendment No. 12 to its Schedule 13D for Phathom Pharmaceuticals, reporting aggregate beneficial ownership of approximately 12.5 million shares (about 15.4% of outstanding common stock, including warrants subject to beneficial ownership limitations). The filing is a routine periodic update with no change in purpose or demands; it reflects the group's ongoing passive investment and does not signal escalation or de-escalation.
- Frazier Life Sciences Public Fund, L.P. directly holds 5,323,356 shares (6.5% of outstanding).
- Frazier Life Sciences IX, L.P. directly holds 5,827,415 shares (7.2%).
- Frazier Life Sciences XI, L.P. directly holds 980,286 shares (1.2%).
- Frazier Life Sciences X, L.P. directly holds 59,403 shares (0.1%).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access